Compare EMBC & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EMBC | GOSS |
|---|---|---|
| Founded | 1924 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 719.7M | 726.8M |
| IPO Year | N/A | 2019 |
| Metric | EMBC | GOSS |
|---|---|---|
| Price | $11.98 | $3.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $18.50 | $8.60 |
| AVG Volume (30 Days) | 781.4K | ★ 3.0M |
| Earning Date | 11-25-2025 | 11-05-2025 |
| Dividend Yield | ★ 5.08% | N/A |
| EPS Growth | ★ 20.90 | N/A |
| EPS | ★ 1.62 | N/A |
| Revenue | ★ $1,080,400,000.00 | $44,051,000.00 |
| Revenue This Year | $2.18 | N/A |
| Revenue Next Year | $0.09 | $6.41 |
| P/E Ratio | $7.28 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.20 | $0.76 |
| 52 Week High | $21.23 | $3.80 |
| Indicator | EMBC | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 41.48 | 73.01 |
| Support Level | $11.46 | $3.34 |
| Resistance Level | $12.11 | $3.80 |
| Average True Range (ATR) | 0.67 | 0.20 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 25.63 | 96.07 |
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.